Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From InterMune, Inc.
The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker
NICE says that Bavencio plus Inlyta will be made available via the Cancer Drugs Fund for advanced kidney cancer while more evidence is collected to support the combination therapy's routine use on the National Health Service.
With the backdrop of Biogen’s BLA filing, and the FDA’s expected response for aducanumab in Alzheimer’s disease in 2020, the link between efficacy and approval seems to have broken. Conditional FDA approvals can’t help when the conditions are ignored.